Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2003 Sep 15;13(18):2961-6.

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.

Author information

1
AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

Abstract

Through chemical modification and X-ray crystallography we identified the 2,4-bis anilino pyrimidines as potent inhibitors of CDK4. Herein, we describe the optimisation of this series.

PMID:
12941312
DOI:
10.1016/s0960-894x(03)00203-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center